David Jones

David Jones


David Jones received his B.Sc. in Physics from Imperial College and then went on to do an M.Sc. in Biochemistry at Kings College London, followed by a PhD in Computational Biology at University College London. After completing a Wellcome Trust Biomathematics Fellowship at UCL, in 1995 he was awarded a Royal Society University Research Fellowship to set up his own lab at the University of Warwick.

In 1999, at 32 years of age, he became the first Professor of Bioinformatics in the UK at Brunel University. In 2001, he was appointed Professor of Bioinformatics at University College London (a joint appointment between the departments of Biochemistry and Computer Science). He is currently the Director of the Bloomsbury Centre for Bioinformatics, a joint research centre between UCL and Birkbeck College. His lab aims to develop and apply state-of-the-art mathematical and computer science techniques to problems now arising in the life sciences, particularly those driven by the post-genomic era.

David's main research interests include protein structure prediction and analysis, simulations of protein folding, applications of Hidden Markov Models, transmembrane protein analysis, machine learning applications in bioinformatics, biological text mining, de novo protein design methodology, and genome analysis including the application of intelligent software agents. He is also the author of a number of very well-known bioinformatics applications: THREADER, GenTHREADER, PSIPRED and MEMSAT, and was one of the original co-authors of the CATH protein structure classification scheme (along with Profs. Christine Orengo and Janet Thornton).

David was also a co-founder of Inpharmatica Ltd., which was founded in 1998 as a spin-out company from University College London and acquired by Galapagos NV in 2007. The company used a combination of bioinformatics and chemoinformatics to look at the relationships between the structure and function of proteins, and the binding of chemical groups to these proteins leading to the discovery of novel drugs.